Improved GPCR ligands from nanobody tethering
Antibodies conjugated to bioactive compounds can allow targeted delivery of therapeutics. Here the authors present a strategy for fusing nanobodies to suboptimal GPCR peptide ligands to potently and selectively activate receptors.
Guardado en:
Autores principales: | Ross W. Cheloha, Fabian A. Fischer, Andrew W. Woodham, Eileen Daley, Naomi Suminski, Thomas J. Gardella, Hidde L. Ploegh |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2020
|
Materias: | |
Acceso en línea: | https://doaj.org/article/2ec526511b22420986044ab4ea9c3e47 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Selective targeting of ligand-dependent and -independent signaling by GPCR conformation-specific anti-US28 intrabodies
por: Timo W. M. De Groof, et al.
Publicado: (2021) -
A nanobody suite for yeast scaffold nucleoporins provides details of the nuclear pore complex structure
por: Sarah A. Nordeen, et al.
Publicado: (2020) -
GPCR_LigandClassify.py; a rigorous machine learning classifier for GPCR targeting compounds
por: Marawan Ahmed, et al.
Publicado: (2021) -
Structure-guided development of heterodimer-selective GPCR ligands
por: Harald Hübner, et al.
Publicado: (2016) -
Nanobody-triggered lockdown of VSRs reveals ligand reloading in the Golgi
por: Simone Früholz, et al.
Publicado: (2018)